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A B S T R A C TObjectives: In early stages of development of new medical technolo-
gies, there are conceptually separate but related societal decisions to
be made concerning adoption, further development (i.e., technical
improvement), and research (i.e., clinical trials) of new technologies.
This article presents a framework to simultaneously support these
three decisions from a societal perspective. The framework is applied
to the 70-gene signature, a gene-expression proﬁle for breast cancer,
deciding which patients should receive adjuvant systemic therapy
after surgery. The “original” signature performed on fresh frozen
tissue (70G-FFT) could be further developed to a parafﬁn-based
signature (70G-PAR) to reduce test failures. Methods: A Markov
decision model comparing the “current” guideline Adjuvant Online
(AO), 70G-FFT, and 70G-PAR was used to simulate 20-year costs and
outcomes in a hypothetical cohort in The Netherlands. The 70G-PAR
strategy was based on projected data from a comparable technology.
Incremental net monetary beneﬁts were calculated to support the
adoption decision. Expected net beneﬁt of development for thesee front matter Copyright & 2013, International S
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ndence to: Manuela A. Joore, Department of Clinic
Center, PO Box 5800, 6202 AZ Maastricht, The Netpopulation and expected net beneﬁt of sampling were calculated to
support the development and research decision. Results: The 70G-
PAR had the highest net monetary beneﬁt, followed by the 70G-FFT.
The population expected net beneﬁt of development amounted to €91
million over 20 years (assuming €250 development costs per patient
receiving the test). The expected net beneﬁt of sampling amounted to
€61 million for the optimal trial (n ¼ 4000). Conclusions: We pre-
sented a framework to simultaneously support adoption, develop-
ment, and research decisions in early stages of medical technology
development. In this case, the results indicate that there is value in
both further development of 70G-FFT into 70G-PAR and further
research.
Keywords: cost-effectiveness analysis, decision modeling, development,
early technology assessment, EVPI, EVSI, value of information.
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In a budget-constrained health care system, regulatory and
reimbursement authorities face two separate but related deci-
sions: whether a technology is cost-effective and thus should be
adopted, and whether existing uncertainty warrants more
research to support this decision [1]. The ﬁrst decision is
answered by choosing the technology with the most favorable
expected mean cost-effectiveness. The second decision is
informed by the expected cost of uncertainty, determined jointly
by the probability that a decision based on existing information
will be wrong and the consequences of a wrong decision. In early
stages of the development of a new health care technology, often
several options concerning the further development of thetechnology exist. Therefore, a decision could be added: is there
value in further development of the new technology? For this
decision, it is analyzed whether a further developed version of a
technology would be seen as favorable compared with other
available technologies. In this analysis, a comparator (the “to-
be-developed” technology) is added to the already available
comparators usually considered for the adoption decision. Any
costs associated with the development of the new technology that
would lead to additional costs per patient in the health care
system can be incorporated in this analysis. Based on this
analysis, regulatory and reimbursement authorities can make
recommendations on whether further developed technologies
would be favored and become the recommended intervention
over and above the other comparators currently in the health careociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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ities an understanding of the direction of innovation that could
maximize health beneﬁts, given currently available evidence.
An example of an innovative technology in its early stages of
development is the 70-gene prognosis signature (MammaPrintTM),
using microarray analysis for patients with breast cancer [2]. Using
the 70-gene signature, the selection of patients who will beneﬁt
most from chemotherapy could be more accurate, which reduces
unnecessary treatment. The promising results of three retrospec-
tive validation studies [3–5] led to a prospective feasibility study
(RASTER: MicroarRAy PrognoSTics in Breast CancER) from 2004
until 2006 [6]. This study was followed by a prospective, random-
ized clinical trial (MINDACT: Microarray In Node-negative Disease
may Avoid ChemoTherapy) that started in 2007 [7]. A recent cost-
effectiveness analysis showed that the 70-gene signature is cost-
effective compared with clinical guidelines, based on the promising
retrospective validation results [8]. The analysis was performed
from a Dutch health care perspective, based on costs per quality-
adjusted life-year (QALY). The incremental cost-effectiveness ratio
was €4600/QALY compared with the next best clinical guideline.
Given a threshold of €30,000/QALY, the probability of the 70-gene
signature being cost-effective compared with usual care was 82%.
In this stage, however, the technology was not yet stable and still
many opportunities were available to improve the test. Based on
the ﬁndings of the feasibility study, a speciﬁc feature of the test
was prioritized for further improvement: the proportion of test
failures [6]. As a consequence of failure, no 70-gene signature can
be derived. Patients who do not receive a 70-gene signature test
result will be treated according to current care [9]. To perform the
70-gene signature, it is essential to collect good-quality breast
tumor RNA in fresh frozen tissue (FFT). In most hospitals as a
routine, however, tumor samples are directly ﬁxed in formalin and
embedded in parafﬁn blocks. It was observed in clinical studies
that the use of FFT leads to more failures compared with using
parafﬁn blocks [6,10]. Also, in a scenario study, 80 breast cancer
experts mentioned the necessity to use FFT to obtain the 70-gene
signature as an important barrier for the successful use of the 70-
gene signature [11]. An opportunity to reduce the proportion of test
failures could thus be the further development of the 70-gene
signature for use on parafﬁn blocks. However, in an early phase, it
was unclear whether it is valuable to invest in such a development.
Recently, three studies were published focusing on early-stage
economic models for medical technologies while acknowledging
the uncertainties concerning technology dynamics inherent in
such a modeling enterprise [12–14]. Girling et al. [12] presented a
method for valuing a new medical technology at the concept stage
from the perspective of manufacturers, while Vallejo-Torres et al.
[13] and Garrison [14] used an iterative approach of decision
analyses by integrating health economic modeling in the product
development cycle. To our knowledge, the three integrated pro-
posed decisions (adoption, further research, and further develop-
ment) have not yet been addressed simultaneously in one study.
Furthermore, the application of the government/reimbursement
authority perspective for these three decisions has not yet been
used. Typically, the costs of reimbursing the intervention will lie
with government or third-party payer organizations, the costs of
the research to reduce uncertainty on existing interventions could
be funded either by government research or by commercial
research, while the costs of further development of the technology
would usually be investments made by the commercial organiza-
tion owning the technology, which would in the end be passed on
to health service purchasers through the price of a technology. In a
health care market, patients (consumers) and doctors (their agents)
are not very well placed to assess the value of a new technology,
based on a synthesis of all available evidence. Therefore, in our
opinion, a health care funder has the responsibility to assess and
signal the value of health innovations on behalf of the population[15]. Under the principle of value-based pricing, a societal perspec-
tive to assess the value of innovation is appropriate. It informs both
the health care funder and the manufacturer on the value of
innovation, and thus the maximum budget and price, given a
certain threshold per QALY.
The present study adds to the existing knowledge by propos-
ing and applying a framework that simultaneously informs three
separate but related decisions: 1) the adoption, 2) further develop-
ment, and 3) further research of the technology. In this article, we
applied the framework to address these three decisions for the
“currently” used clinical guideline Adjuvant! Online (AO), the
“original” 70-gene signature performed on FFT, and the “to-be-
developed” 70-gene signature performed on parafﬁn blocks.Methods
Analytical Framework
The analytical framework consists of three decisions (adoption,
development, and research). The methodology for answering
each of these three questions is described below.
Adoption Decision
The adoption decision depends on the expected net monetary
beneﬁt (NMB) of all alternative technologies. Imagine j ¼ 0 to T
different technologies are considered. These would be numbered
j0, j1, … , jT. Imagine also that there are uncertain parameters
concerning the clinical and economic performance of these
technologies, which we denote as a vector θ. And, imagine we
have a model that estimates the NMB of treatment j, given
particular values of θ such that the NMB ¼ NMB(j, θ) [16]. This,
in turn, is based on the estimated health outcomes (H; e.g.,
QALYs), which is provided by treatment j, for a speciﬁc vector
of values θ, that is, H(j, θ) and a cost function C(j, θ) such that
NMB for a specific value of θ is: NMBðj,θÞ ¼ λ Hðj,θÞ – Cðj,θÞ ð1Þ
with λ being society’s willingness to pay for additional health.
On the basis of the set of technologies, the model, and
distributions for the uncertain parameters θ, one can undertake
probabilistic sensitivity analysis. This integrates over the uncer-
tain values of θ to estimate the expected NMB of each technology.
Expected NMB for treatment strategy j is: Eθ½NMBðj,θÞ ð2Þ
And this enables us to estimate the best treatment given
current information on the parameters. This best treatment we
denote as j*, which is the particular j that gives the maximum
expected net beneﬁt, that is,
jn is the j that gives specific value of θ is: maxjfEθ½NMBðj,θÞg ð3Þ
Development Decision
In this article, we argue that further development of one of the
technologies (original technology jorig into the technology jdev) is
an additional option available to the decision makers. Having this
new option changes the decision architecture. First of all, there
might be parameters θdev speciﬁc to the developed technology.
When added together with the parameters for the existing
technologies, these create a new set of uncertain model param-
eters:
θnew ¼ ðθ,θdevÞ ð4Þ
Also, we have a new possible strategy for which we will
calculate an NMB.
NMB of the to−be−developed technology is:
NMBðjdev,θnewÞ¼ λ  Hðjdev,θnewÞ − Cðjdev,θnewÞ ð5Þ
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technology to society per person receiving the technology, that is, C
(jdev, θnew). These costs are, in turn, likely to be a function of the
total costs of the development of the technology faced by the
manufacturer. These costs will depend on factors such as the
nature of the development and may also depend on some of the
uncertain parameters θnew. It is reasonable to assume that at least
part of these costs will be faced by society (the reimbursement
agency) through the price of the developed technology. The pro-
portion of these costs that is faced by society might depend on the
relative market size of the jurisdiction, the extent to which the
manufacturer needs to recoup development costs, and proﬁt from
investments made in this development and others, which may or
may not come to fruition. One might conceive of the costs to society
per individual recipient of the developed technology jdev as the costs
to society of the original treatment j, plus some additional costs of
development to be borne by society:
Cðjdev,θnewÞ ¼ Cðj,θnewÞ þ CDevToSocietyðjdev,θnewÞ ð6Þ
The expected net beneﬁt per individual recipient of the to-be-
developed technology jdev given current information is given by
Eθnew½NMBðjdev,θnewÞ ¼ λ Hðjdev,θnewÞ − Cðjorig,θnewÞ
− CDevToSocietyðjdev,θnewÞ ð7Þ
If the expected NMB of the to-be-developed technology jdev is
greater than the expected NMB of the best technology (i.e., if
Eθnew[NMB(jdev, θnew)] 4 Eθnew[NMB(j*, θnew)]), then one would
consider jdev to be the most cost-effective of the options available
at this time. This implies that there is value to society in
developing the technology. The increment between the expected
NMB of the to-be-developed technology jdev and the expected NMB
of the best technology j* can be perceived as the expected net
beneﬁt of development (ENBD) per individual recipient of the to-
be-developed technology jdev:
ENBD ¼ Eθnew½NMBðjdev,θnewÞ − Eθnew½NMBðjn,θnewÞ ð8Þ
The population-level ENBD is given by multiplying the ENBD
by the number of people affected by the decision over the lifetime
of the technology (P):
Population ENBD ¼ P  ðEθnew½NMBðjdev,θnewÞ − Eθnew½NMBðjn,θnewÞÞ
ð9Þ
Research Decision
On the basis of the model for the adoption and development
decision, we can imagine obtaining further information to reduce
uncertainty in some or all of the uncertain parameters θnew.
If we imagine having complete certainty on all the parame-
ters, then we would be able to choose the treatment strategy that
gives the maximum net beneﬁt without any uncertainty being
involved. The expected NMB of knowing the true underlying
value of θnew is Eθ[maxj{NMB(j, θnew)}]. Therefore, the expected
additional value of knowing the true values of θnew, or the
expected value of perfect information (EVPI) [17,18], is
EVPI ¼ Eθ½maxjfNMBðj,θnewÞg − Eθ½NMBðjn,θnewÞ ð10Þ
The population-level EVPI is given by multiplying the EVPI by
the number of people affected by the decision over the lifetime of
the technology (P):
Population EVPI ¼ P  ðEθ½maxjfNMBðj,θnewÞg − Eθ½NMBðjn,θnewÞÞ
ð11Þ
In practice, research is likely to result in information on only
some of the parameters. Therefore, one would like to calculate
the expected value of perfect parameter information (EVPPI).
Imagine obtaining perfectly certain information on only someparameters, splitting θnew into two components θnew ¼(φ, ψ), and
obtaining perfect information only on the subset φ.
Partial EVPIðφÞ, i:e:, EVPPI ¼ Eφ½maxjfEψ jφ½NMBðj,φ,ψÞg
− Eθ½NMBðjn,θnewÞ ð12Þ
We can also imagine obtaining sample information, that is
data X collected in a particular sample size for a particular follow
time, etc. This sample information may, for instance, provide
reduced uncertainty in the parameters θ such that the posterior
probability distributions for θ given X exhibit, for example,
smaller credible intervals for the parameters θ. Then, we can
compute the expected additional value of this sample informa-
tion to the decision making as [19,20]:
EVSIðXÞ ¼ EX½maxjfEθjX½NMBðj,θjXÞg − Eθ½NMBðjn,θnewÞ ð13Þ
At the population level, this is
Population EVSIðXÞ ¼ P  ðEX½maxjfEθjX½NMBðj,θjXÞg − Eθ ½NMBðjn,θnewÞÞ
ð14Þ
Obtaining sample information, that is, data collection, is likely
to be associated with costs for the decision maker. Let us refer to
these costs as C(X). The net value of the data X to the decision
maker, the expected net beneﬁt of sampling (ENBS) [21], is as
follows:
ENBSðXÞ ¼ P  ðEX½maxjfEθjX½NMBðj,θnewjXÞg − Eθ ½NMBðjn,θnewÞÞ − CðXÞ
ð15Þ
Case Description
In early node-negative estrogen-receptor–positive breast cancer
patients after local therapy (surgery with or without radiotherapy),
prognostic tests are used to distinguish between patients with a
high and a low risk of developing metastases. High-risk patients
receive hormonal therapy and chemotherapy, while low-risk
patients receive only hormonal therapy. In standard care, a
prognostic test based on clinicopathological criteria, the clinical
guideline AO software, is used [9]. Recently, genetic tests such
as the 70-gene signature that could be used instead of the
clinicopathological criteria have become available [3–5]. The original
70-gene signature is performed on fresh frozen tissue samples
(70G-FFT). The majority of the hospitals, however, are used to
preparing and storing the tissue after surgery on parafﬁn blocks.
They are not used to working with FFT samples. Research has
shown that the use of FFT samples is associated with failures of the
70G-FFT [6]. This has led to the question whether there would be
value to society in developing a 70-gene signature based on parafﬁn
blocks (70G-PAR). Previously, a probabilistic Markov decision model
was developed to assess the effects (QALYs), costs, and cost-
effectiveness of the use of the 70G-FFT instead of the AO alone in
patients with early, node-negative, estrogen-receptor–positive
breast cancer [8]. In each strategy, on the basis of the sensitivity
and speciﬁcity of the prognostic test, patients were classiﬁed as
having a true low, true high, false low, or false high risk of
developing metastasis. The sensitivity and speciﬁcity of each
prognostic test were calculated from a database consisting of three
previously reported validation studies [3–5]. From this database, a
total of 305 untreated, node-negative and estrogen-receptor–pos-
itive tumor samples were selected and classiﬁed by the 70-gene
signature and the clinical pathological guidelines as low or high risk
of developing distant metastasis in 10 years. After local therapy, the
high-risk patients received hormonal therapy and chemotherapy,
while low-risk patients received only hormonal therapy.
Model Description
The model simulated the course of events in a hypothetical
cohort of patients aged 50 years. The calculations were performed
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600 possible trial results the Monte Carlo simulation with 5000
iterations was run to calculate the corresponding EVSI. Subse-
quently, the 600 EVSI estimates were averaged to obtain an
expected EVSI for that sample size. Future costs and effects were
discounted to their present value by a rate of 4% and 1.5% per
year, respectively, according to Dutch guidelines [22]. We pro-
grammed the model in Microsoft Excel (Microsoft, Redmond, WA).
For the purpose of the current study, an additional alternative
was added to the above-described decision model: the developed
technology 70G-PAR. It was assumed that this, not yet available,
technology would resemble the original 70-gene signature (70G-
FFT), except for the proportion of failures and the costs. There-
fore, two new uncertain model parameters were incorporated
into the model: a failure parameter and a parameter to reﬂect the
additional cost of development of 70G-PAR to society per indi-
vidual recipient of the test. The failure parameter reﬂects a
technical failure in the process of the preparation of the tumor
sample for the 70-gene signature. These failures may take place
during surgery, at the pathology department, during transport of
the sample, or during the performance of the test itself. In the
case of a technical failure, the 70-gene signature cannot be
determined and treatment will be based on the currently used
clinical guideline (AO). The accuracy of the developed technology
(70G-PAR) is equal to the accuracy of the original technology
(70G-FFT). 70G-PAR, however, is likely to have fewer failures. As a
result, the 70-gene signature result will be available for more
patients. The failure rate of the 70G-FFT was based on the
RASTER study. Observed failures (N ¼ 158) in this study included
less than 50% tumor cells in the sample (75), tumor too small for
biopsy (39), insufﬁcient RNA quality (14), 28 samples already
prepared in formalin, 1 sample stored too long in RNA later,
and 1 sample lost in mail [6]. Based on these data, the mean 70G-
FFT failure rate was estimated to be 27%. This was modeled as aTable 1 – Parameter input and results.
AO 70G-FFT
Input
Sensitivity 0.57 0.74
Speciﬁcity 0.54 0.58
Unit cost €0 €2,675
Development cost
Failure 0 0.27
€ Chemotherapy €8,596 €8,596
Results
% Chemo 48% 46%
€ €27,188 €28,080
QALY 12.75 12.92
NMB† €355,364 €359,520
ENBD
Population ENBD
EVPI €528
Population EVPI €56 million
EVPPI
Population EVPPI
ENBS €61 million
AO, Adjuvant Online; ENBD, expected net beneﬁt of development; ENBS
information; EVPPI, expected value of perfect parameter information; NM
70-gene-fresh frozen tissue; 70G-PAR, 70-gene signature based on parafﬁ
 This are the additional costs of development of the 70G-PAR per recip
† Based on a threshold of €30,000 and original costs and QALYs before r
‡ Based on the comparison of the NMBs of 70G-PAR and the best alternabeta distribution with a standard error of 2% (α 158; β 427) [8]. The
mean failure rate of the 70G-PAR was set equal to the observed
failure rate of the 21-gene assay (8%), which is a parafﬁn-based
gene expression proﬁle for the same patient group [10]. The
failure rate of the 70G-PAR was modeled by using a beta pert
distribution (the beta pert distribution emphasizes the “most
likely” value over the minimum and maximum estimates) with a
range from 0% to 27%. The upper limit of the range was based on
the assumption that the failure rate of 70G PAR will not be worse
than that of the 70G FFT. It was assumed that no failures
occurred in the AO strategy. In the case of failure in the
preparation of the tumor sample for either the 70G-FFT or the
70G-PAR, the 70-gene kit is not (entirely) used, and only 10% part
of the costs of the 70-gene kit are made [6]. Therefore, the costs in
the case of a failure of both 70-gene signatures were assumed to
be 10% of the total costs of the test. The mean costs per patient of
the 70G-PAR were assumed to amount to the costs of the 70G-
FFT, increased with the additional cost of development of 70G-
PAR to society per patient receiving the test. For these additional
costs of the 70G-PAR, a central estimate of €250 per patient
receiving the test was used. This is based on the costs of
comparable arrays on parafﬁn blocks. However, because we are
not certain that this will be the same for the 70-gene signature,
this uncertainty was incorporated by using a uniform distribution
between €0 and €500. For details of the model, see Retèl et al. [8].
Model Analyses
Adoption decision
To obtain the expected NMB for the AO and the 70G-FFT, we
performed a probabilistic sensitivity analysis with 5000 iterations
[23]. We calculated the NMBs on the basis of a societal willingness
to pay (λ) of €30,000/QALY. This resembles the £20,000 to 30,000/
QALY threshold used by the National Institute for Health andAO 70G-FFT 70G-PAR
0.57 0.74 0.74
0.54 0.58 0.58
€0 €2,675 €2,675
€300
0 0.27 0.08
€8,596 €8,596 €8,596
48% 46% 46%
€27,188 €28,080 €28,490
12.75 12.92 12.96
€355,364 €359,520 €360,384
€864‡
€91 million
€702
€74 million
€644
€65 million
, expected net beneﬁt of sampling; EVPI, expected value of perfect
B, net monetary beneﬁt; QALYs, quality-adjusted life-years; 70G-FFT,
n blocks.
ient of the test borne by society.
ounding.
tive (70G-FFT).
Fig. 1 – Analytical framework.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 2 0 – 7 2 8724Care Excellence in the United Kingdom [24,25]. To show decision
uncertainty, cost-effectiveness acceptability curves (CEACs) were
constructed. We performed a one-way sensitivity analysis on
discount rate, using the rate advised by the National Institute for
Health and Care Excellence (3.5% for effects and costs) [26].
Development decision
The expected NMB of the 70G-PAR was calculated, and CEACs
were constructed to show uncertainty in deciding on which of the
three technologies was cost-effective: AO, 70G-FFT, or 70G-PAR.
Subsequently, the ENBD, the incremental NMB of 70G-PAR versus
the best technology, was calculated. We conducted a one-way
sensitivity analysis for a range of ﬁxed values (€0, €100, €200,
€300, €400, and €500) of the development costs of 70G-PAR per
recipient of the test that are borne by society. Also, we calculated
the probability that the ENBD was positive for each of these
values. Finally, the population ENBD was calculated by multi-
plying the ENBD per patient by the number of people affected by
the decision over the lifetime of the technology (P). P was
estimated to be 105,442 on the basis of an annual incidence of
12,500 early breast cancer patients in The Netherlands [27], a
lifetime of the technology of 10 years, and a discount rate of 1.5%.
Research decision
First, the EVPI was calculated on the basis of 50,000 simulations
(10  5000 simulations) for the two decision architectures: AOversus 70G-FFT, and AO versus 70G-FFT versus 70G-PAR. Sub-
sequently, the EVPPI based on the latter decision architecture was
calculated for the following groups of parameters: test accuracy
(sensitivity and speciﬁcity), costs, utilities, and failure rates.
EVPPI calculations were based on 2000 outer loops and 200 inner
loops. For the group of parameters with the highest EVPPI, we
computed the expected additional value of sample information to
the decision making.Results
Adoption Decision
The total expected costs per patient over 20 years were €28,080
for the 70G-FFT and €27,188 for the AO. The 70G-FFT yielded
12.92 QALYs, and the AO yielded 12.75 QALYs. The expected
NMB amounted to €359,520 for the 70G-FFT and €355,364 for the
AO (see Table 1). Because it had the highest expected NMB,
70G-FFT was found to be cost-effective. The CEAC shows that
the 70G-FFT had the highest probability of being cost-effective if
willingness to pay exceeds €5,000/QALY (see Fig. 2A). The
one-way sensitivity analysis regarding discount rates of 3.5%
resulted in a smaller difference in expected NMB (€3210 instead of
€4156).
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Fig. 2 – (A) Cost-effectiveness acceptability curve (CEAC) of the 70-gene signature versus AO. (B) CEAC of the 70-gene signature
FFT versus 70-gene signature PAR versus AO. AO, Adjuvant Online; FFT, fresh frozen tissue; PAR, parafﬁn blocks.
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For the 70G-PAR, the total expected costs were €28,490 and the
total expected QALYs were 12.96. The expected NMB of the 70G-
PAR amounted to €360,384. Because 70G-PAR had the highest
expected NMB, it was found to be cost-effective (Fig. 1B). The
CEAC comparing all three technologies shows that the 70G-PAR
has the highest probability of being cost-effective if willingness to
pay exceeds €8,000/QALY (see Fig. 2B). The probability of 70G-PAR
being cost-effective at a threshold of €30,000/QALY was 76%. The
ENBD amounted to €864 (Table 1). The ENBD multiplied by the
population gives us the population ENBD of €91million.
The results of the sensitivity analysis on the value of the
development costs of 70G-PAR per recipient of the test that are
borne by society are shown in Figure 3. If the development costs
are €0, the ENBD amounted to €1103, and the population ENBD to
€116 million. This implies that the maximum budget for develop-
ment is 116 million. If the development costs increase to €500 perpatient, the ENBD amounted to €606, and the population ENBD to
€64 million. At a threshold of €30,000/QALY, the probability that
the ENBD was positive ranged from 0.82 (€0 development costs) to
0.68 (€500 development costs) (Fig. 3).
Research Decision
The population EVPI for the decision between the currently
available technologies AO and 70G-FFT amounted to €56 million
(Fig. 4B). The population EVPI in the decision architecture com-
paring all three technologies amounted to €74 million (Fig. 4A). In
the latter context, the EVPPI for test accuracy (sensitivity and
speciﬁcity of AO, 70G-FFT, and 70G-PAR) was €65 million. For the
other groups of parameters, including the probability of failure of
the 70G-FFT and 70G-PAR and the development costs of 70G-PAR,
the EVPPI was negligible (calculations took around 1200 min on a
Core i5 computer). Therefore, it was deemed most valuable to
obtain sample information regarding the accuracy of the
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Fig. 3 – Expected net beneﬁt of development (ENBD) for the
population and associated uncertainty for a range of costs of
development for society.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 2 0 – 7 2 8726technologies. For this purpose, we envisioned a trial resembling
the ongoing MINDACT trial [28]. In this trial, patients received
both AO and the 70-gene signature. (Because the accuracy of the
70-gene signature is not dependent on whether the test is
performed on FFT [70G-FFT in the case] or on a parafﬁn block
([70G-PAR in the case)], it is not relevant which of the versions of
the 70-gene signature will be used in this possible future trial. Of
course, in the on going MINDACT trial, the 70G-FFT was used,
because the 70G-PAR was not yet available.) Subsequently,
patients with a discordant test result (low-risk AO vs. high-risk
70-gene signature, or high-risk AO vs. low-risk 70-gene signature)
were randomized to be treated according to either the AO or the
70-gene signature test result. The trial costs were estimated to be
€1000 per patient [28]. Figure 5 shows that the optimal sample
size of this trial was around n ¼ 4000, with an EVSI of €65 million.
The total trial costs amount to 4 million, resulting in an ENBS of
€61 million.
A summary of the results is depicted in the framework shown
in Figure 1.Discussion
This article presented a framework to simultaneously address
decisions with regard to the adoption, further development, and
further research of a new, still dynamic, technology in an early
stage of diffusion. The framework was applied to the 70-gene
signature, a gene expression proﬁle for patients with breast
cancer.
The results show that in this case, the to-be-developed
technology, 70G-PAR, has the highest probability of being cost-
effective compared with the original technology, 70G-FFT, and
current care (AO), if the willingness to pay for one additional
QALY exceeds €8,000. The expected net beneﬁt of development
for the population is positive and amounts to €91 million. The
value of development is sensitive for changes in the development
costs per recipient of the test to society of the 70G-PAR. The net
value of further research, envisioned as a study on the accuracy
of the 70-gene signature, amounts to €61 million (65 million
minus trial costs of 4 million). The results indicate that there is
both value in the further development of the 70G-FFT into a
parafﬁn based test, the 70G-PAR, and value in further research
into the accuracy of the 70-gene signature.
The suggested framework draws on probabilistic decision
analytical modeling, which can be considered standard practice
to inform adoption and research allocation decisions regarding
available technologies. To be able to add a still-to-be-developed
technology to a decision model, adaptations are likely to benecessary. In the case we presented, the 70G-PAR, a still-to-be-
developed parafﬁn-based test, is thought to yield an advantage to
the original 70G-FFT in terms of failures. At the same time, the
70G-PAR may also be associated with additional costs to society.
These two aspects of the to-be-developed technology could be
incorporated into a previously used decision model to investigate
the original 70G-FFT compared with current care relatively easy.
Of course, in other cases adapting the model to incorporate a
still-to-be-developed technology may require the addition or
alteration of other aspects of the model (such as improved
efﬁcacy, or fewer side effects). Also, in other cases, the necessary
adaptations to the model may be more complicated than the
ones shown in this article. In addition, in other cases, it may be
more complicated to anticipate the possible advantages and
disadvantages of a possible future development of a technology.
Furthermore, in the case of the 70-gene signature, we mod-
eled only one direction of development, because for this case this
was the most realistic option. In reality, however, several direc-
tions for further development may be indicated instead of just
one. The identiﬁcation of directions of development may be
based on quantiﬁable diffusion scenarios [11].
With regard to the necessary input data to model the devel-
oped technology, in our case, evidence was available to obtain a
central estimate and an estimate of the uncertainty in the added
parameters (failure rate and development costs). For other cases,
however, evidence may be lacking, forcing researchers to use
expert opinion. Recently, Bojke et al. [29] described a method to
obtain expert elicitation and use this by parameterizing the
information, including the existing uncertainty, directly into
the model.
In case both research and development are valuable, we need
to decide on the order in which these activities should take place.
For example, it may be better to wait for additional evidence
before we start further development. Waiting could be an inter-
esting option because it may prevent wasting a considerable
amount of money, if the developed technology turns out not to be
cost-effective. However, waiting may result in health beneﬁts
forgone, if the developed technology yields the highest health
beneﬁt. An argument to start development before conducting
further research is that development may also reduce uncer-
tainty. For example, it is possible that the cost of development
becomes more certain during development than it is a priori.
To inform the decision whether we should wait to further
develop a technology until more evidence is available, a trade-
off should be made between the costs and beneﬁts of the differ-
ent options: research and development, ﬁrst research, ﬁrst
development. A useful technique to assist in making such
trade-offs is real options analysis (ROA) [30]. ROA stems from
the ﬁnancial literature, but was recently introduced as an
addition to the value of information framework [31]. Its advant-
age is that it not only considers whether the beneﬁts of (devel-
oping) a technology outweigh its costs (as in cost-effectiveness
analyses) but also recognizes the option to postpone the adoption
or development of the technology. It can then assist the trade-off
between adopting a new technology and waiting for more
evidence. If the analyses in the proposed framework show that
both further development and further research are valuable, ROA
can be used in a similar way to assist the trade-off between
conducting both simultaneously, and postponing either develop-
ment or research. Because it requires an additional set of
parameters and assumptions, ROA was beyond the scope of the
present article. We acknowledge, however, its potential value for
the proposed framework, and emphasize that it is an important
area for further research.
Previously, publications focused on the evaluation of technol-
ogies early in the product life cycle [12–14]. They focused on the
dynamic nature of the technology under investigation, indicating
Fig. 4 – (A) Expected value of perfect information (EVPI) curve of the 70-gene signature versus AO. (B) EVPI curve of the 70-gene
signature FFT versus 70-gene signature PAR versus AO. AO, Adjuvant Online; FFT, fresh frozen tissue; PAR, parafﬁn blocks.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 2 0 – 7 2 8 727the need for iterative assessments. Garrison [14] is highlighting
the linkage between the concept of economic value in cancer care
and the incentives for innovation. In this study, the key point is
that value is also a dynamic and moving target, which is often
not taken into account. Our framework gives an example of a
technology in its early stages, where the type of tumor sample
used has been questioned, as a result of the identiﬁcation of
barriers for more successful use of the technology in clinical
practice. An evaluation of barriers for successful implementa-
tion, the calculation of the expected net beneﬁt of the further
development of a technology that could possibly overcome
these barriers, as well as the calculation of the value of further
research should ideally be an iterative process. This process
could start all over again if new information becomes available,
as a result of the development of the technology, evidence from
research, or both. Girling et al. [12] developed a framework forvaluing new medical devices at the concept stage that balances
beneﬁt to the health care provider against commercial costs.
They conclude that quantiﬁable uncertainty that can be
resolved before the device is brought into the market will
generally enhance early-stage valuations of the device, and
this remains true even when some components of uncertainty
cannot be fully described. Both articles adopt a perspective from
the manufacturer and focus on technology development alone.
None of these studies simultaneously addresses the value of
research and the value of development from a societal perspec-
tive. In the societal perspective, the effects and costs are
considered regardless of who experiences the beneﬁts or pays
the costs. Our study was performed from a societal perspective.
In our opinion, a health care funder has the responsibility to
assess and signal the value of health innovations on behalf of
the population. Under the principle of value-based pricing, a
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V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 2 0 – 7 2 8728societal perspective informs both the health care funder and
the manufacturer on the value of innovation, and thus the
maximum budget and price, given a certain threshold per
QALY. Obviously, it is the manufacturer’s decision whether or
not to actually incorporate the additional development costs
into the price of the technology.
The framework presented in this article can be used to
inform three conceptually separate but related questions: 1)
what is the value of adoption? 2) what is the value of further
development? and 3) what is the value of research? This
framework can support investment decisions for further devel-
opment or research in early stages in the development of health
care technologies.Acknowledgments
We are indebted for the efforts of the coeditor. Any remaining
errors are the responsibility of the authors alone.
Source of ﬁnancial support: This study was funded by the
Dutch Health Care Insurance Board (DHCIB), The Netherlands.
The DHCIB had no role in the study design and the collection,
analysis, and interpretation of data and the writing of the article
and the decision to submit it for publication.
R E F E R E N C E S[1] Claxton K, Sculpher M, Drummond M. A rational framework for
decision making by the National Institute for Care Excellence (NICE).
Lancet 2002;360:711–5.
[2] Vanʼt Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression
proﬁling predicts clinical outcome of breast cancer. Nature
2002;415:530–6.
[3] van de Vijver MJ, He YD, van ‘t Veer LJ, et al. A gene-expression
signature as a predictor of survival in breast cancer. N Engl J Med
2002;347:1999–2009.
[4] Buyse M, Loi S, van’t Veer L, et al. Validation and clinical utility of a
70-gene prognostic signature for women with node-negative breast
cancer. J Natl Cancer Inst 2006;98:1183–92.
[5] Bueno-de-Mesquita JM, Linn SC, Keijzer R, et al. Validation of 70-gene
prognosis signature in node-negative breast cancer. Breast Cancer Res
Treat 2009;117:483–95.
[6] Bueno-de-Mesquita JM, van Harten W, Retel V, et al. Use of 70-gene
signature to predict prognosis of patients with node-negative breastcancer: a prospective community-based feasibility study (RASTER).
Lancet Oncol 2007;8:1079–87.
[7] Cardoso F, Van’t Veer L, Rutgers E, et al. Clinical application of the
70-gene proﬁle: the MINDACT trial. J Clin Oncol 2008;26:729–35.
[8] Retèl VP, Joore MA, Knauer M, et al. Cost-effectiveness of the 70-gene
signature versus St. Gallen guidelines and Adjuvant Online for early
breast cancer. Eur J Cancer 2010;46:1382–91.
[9] Sparano JA, Paik S. Development of the 21-gene assay and its
application in clinical practice and clinical trials. J Clin Oncol
2008;26:721–8.
[10] Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in
making decisions about adjuvant therapy for women with early breast
cancer. J Clin Oncol 2001;19:980–91.
[11] Retèl VP, Joore MA, Linn SC, et al. Scenario drafting to anticipate
future developments in technology assessment. BMC Res Notes
2012;5:442.
[12] Girling A, Young T, Brown C, et al. Early-stage valuation of medical
devices: the role of developmental uncertainty. Value Health
2010;13:585–91.
[13] Vallejo-Torres L, Steuten LM, Buxton MJ, et al. Integrating health
economics modeling in the product development cycle of medical
devices: a Bayesian approach. Int J Technol Assess Health Care
2008;24:459–64.
[14] Garrison LP Jr. Rewarding value creation to promote innovation in
oncology: the importance of considering the global product life cycle.
Oncologist 2010;15(Suppl. 1):49–57.
[15] Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs:
an opportunity not to be missed? BMJ 2008;336:251–4.
[16] Buxton MJ. Economic evaluation and decision making in the UK.
Pharmacoeconomics 2006;24:1133–42.
[17] Briggs A, Claxton K, Sculpher M. Decision-making, uncertainty and the
value of information. In: Decision Modelling for Health Economic
Evaluation. Oxford, UK: Oxford University Press, 2006: chapter 6.
[18] Claxton K, Cohen JT, Neumann PJ. When is evidence sufﬁcient? Health
Aff (Millwood) 2005;24:93–101.
[19] Willan AR, Pinto EM. The value of information and optimal clinical trial
design. Stat Med 2005;24:1791–806.
[20] Briggs A, Claxton K, Sculpher M. Efﬁcient research design. In: Decision
Modelling for Health Economic Evaluation. Oxford, UK: Oxford
University Press, 2006: chapter 7.
[21] Claxton K, Posnett J. An economic approach to clinical trial design and
research priority-setting. Health Economics 1996;5:513–24.
[22] Oostenbrink JB, Koopmanschap MA, Rutten FFH. Manual for Cost
Analyses, Methods and Standard Prices for Economic Evaluations in
Health Care. Amstelveen, The Netherlands: Dutch Health Insurance
Executive Board, 2006 (in Dutch).
[23] Weinstein MC. Recent developments in decision-analytic modelling for
economic evaluation. Pharmacoeconomics 2006;24:1043–53.
[24] Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the
role of cost-effectiveness acceptability curves. Health Econ 2001;10:
779–87.
[25] Lothgren M, Zethraeus N. Deﬁnition, interpretation and calculation
of cost-effectiveness acceptability curves. Health Econ 2000;9:
623–30.
[26] National Institute for Health and Care Excellence. Guide to the Methods
of Technology Appraisal. London, UK: National Institute for Health and
Care Excellence, 2008. Available from: www.nice.org.uk. [Accessed
October 25, 2012].
[27] Dutch Comprehensive Cancer Centres. The incidence of breast cancer
in The Netherlands in 2007. Available from: http://www.cijfersover
kanker.nl/selecties/Incidentie_borstkanker/img5118c67713231.
[Accessed July 15, 2013].
[28] Rutgers EJT, Piccart-Gebhart MJ, Delaloge S, et al. The EORTC 10041/BIG
03-04 MINDACT trial is feasible: ﬁrst results of the pilot phase. Eur J
Cancer 2011;47(18):2742–9.
[29] Bojke L, Claxton K, Bravo-Vergel Y, et al. Eliciting distributions to
populate decision analytic models. Value Health 2010;13:557–64.
[30] Eckermann S, Willan AR. Expected value of information and decision
making in HTA. Health Econ 2007;16:195–209.
[31] Grutters JPC, Abrams KR, De Ruysscher D, et al. When to wait for more
evidence? Real options analysis in proton therapy. Oncologist
2001;16:1752–61.
